Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic continues acquisition streak

This article was originally published in The Gray Sheet

Executive Summary

Hologic will bring in house the production of amorphous selenium photoconductor materials and coatings used in its Selenia full-field digital mammography systems through the $26.7 mil. purchase of German component supplier AEG Elektrofotografie May 2. The purchase price for AEG, the sole supplier of the component, represents about half of AEG's 2005 revenue. The deal follows Hologic's recent acquisitions of R2 Technology and Suros Surgical Systems (1"The Gray Sheet" May 1, 2006, p. 11)...

You may also be interested in...



Hologic Expands Mammography Offerings With Purchase Of CAD Firm R2

Hologic will work to convert existing R2 customers who still use film-based detectors to digital systems following the $220 mil. purchase of the computer-aided detection firm on April 24

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel